You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Conformational Stabilization of the HIV-1 Env Trimer

    SBC: AVATAR MEDICAL, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Avatar is developing HIV vaccine immunogens based on dityrosine DT crosslinking of soluble native Env gp trimers Several of the most potent broadly neutralizing Abs andquot bnAbsandquot preferentially bind native Env trimers and a trimeric immunogen thus would both present a wide range of key neutralizing epitopes and simultaneously focus immune responses away fro ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A Rapid Portable HIV Detection and Monitoring System for Low Resource Settings

    SBC: THERMAL GRADIENT, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Rapid Portable HIV Detection and Monitoring System The long term objectives of this project are Develop a prototype of a rapid portable instrument for detecting and measuring the amount of Human Immunodeficiency Viruses HIVandapos s in samples of patient blood particularly in low resource settings Carry out a pilot study to establish the effectivene ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Non-Invasive Treatment for Uveitis

    SBC: ACIONT, INC.            Topic: N

    DESCRIPTION provided by applicant The aim of this innovative proposal is to commercialize a non invasive topical product that treats uveitis which is safe and easy to administer Uveitis is the third leading cause of blindness in the United States Heretofore the primary treatment of intermediate and posterior uveitis has been either oral medications with significant systemic side effects or ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Approach-specific, multi-GPU, multi-tool, high-realism neurosurgery simulation

    SBC: KITWARE INC            Topic: 100

    DESCRIPTION provided by applicant Approach specific Multi GPU Multi tool High realism Neurosurgery Simulation Surgical treatment of neurological diseases is complicated and requires advanced training However compressed internship schedules in hospitals creates a challenge to young surgeons to master techniques needed for such complex procedures Surgical simulators are powerful tools to p ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. A Multi-channel Web Platform to Provide Holistic Care to Underserved Consumers

    SBC: Transcendent International, LLC            Topic: NIMHD

    DESCRIPTION provided by applicant Significant obstacles exist in care delivery that prevents meaningful utilization of mental health services by consumers who experience health disparities Specifically individuals facing isolation due to linguistic literacy or cultural bariers often face challenges in procuring mental health care These challenges are in part due to the medical and mental systemsan ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

    SBC: GLYCOMIRA, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults In the most severely affected progression of this inflammatory process to the deeper periodontal ligaments and alveolar bone results in tooth loss from loss of mandibular anchorage Gingivitis and periodontitis are initiated by chronic infection o ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC Modern HIV therapy combines drugs from different classes to form andquot cocktailandquot therapies that have significantly prolonged the lives of many HIV patients However side effects and drug resis ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Peptidomic Rapid Point-of-Care TB Diagnostic

    SBC: NEW YORK UNIVERSITY            Topic: NIAID

    DESCRIPTION (provided by applicant): Diagnosis of active tuberculosis (TB) in TB-endemic countries, where gt90% of the global TB cases occur, depends upon microscopic examination of sputum smears made directly from the specimen. While this test is highly specific, the test is tedious, time-consuming, requires multiple patient visits, and has limited and variable sensitivity WHO has repeatedly expr ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. High throughput tau oligomer drug screening assay for Alzheimer's disease

    SBC: OLIGOMERIX INC            Topic: NIA

    DESCRIPTION (provided by applicant): There is a very large and rapidly growing unmet need for disease-modifying drugs for Alzheimer's disease (AD) as its prevalence is increasing worldwide due to demographic shifts in the aging population. AD is the thirdmost costly disease in the US with direct costs over 200 billion annually. The proposed phase IIB program is for the continued development ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government